Asthma is a complex disease with a variable course. Efforts to
identify biomarkers to predict asthma severity, the course of
disease and response to treatment have not been very successful
so far. Biomarker research has expanded greatly with the
advancement of molecular research techniques. An ideal
biomarker should be suitable to identify the disease as well the
specific endotype/phenotype, useful in the monitoring of the
disease and to determine the prognosis, easily to obtain with
minimum discomfort or risk to the patient. An ideal biomarker
should be suitable to identify the disease as well the specific
endotype/phenotype, useful in the monitoring of the disease and
to determine the prognosis, easily to obtain with minimum
discomfort or risk to the patient - exhaled breath analysis, blood
cells and serum biomarkers, sputum cells and mediators and urine
metabolites could be potential biomarkers of asthma bronchiale.
Unfortunately, at the moment, an ideal biomarker doesn’t exist and
the overlap between the biomarkers is a reality. Using panels of
biomarkers could improve probably the identification of asthma
endotypes in the era of precision medicine.